NCT00942734View on ClinicalTrials.gov

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Head And Neck Cancer
Interventions
DRUG

Erlotinib

One tablet (150 mg) by mouth every day of each 28 day study cycle.

DRUG

RAD001

1 tablet (5 mg) by mouth every day of each 28 day study cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00942734 - Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter